Focus on human microbiome to fight liver cirrhosis

22 European institutions join forces in MICROB-PREDICT to improve the prevention and treatment of chronic liver disease (cirrhosis). We aim to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis), when such decompensated cirrhosis will progress to acute-on-chronic liver failure (ACLF), and a patient’s individual treatment response. Based on such biomarkers, we strive to develop novel diagnostic tools for earlier and better patient stratification and to establish personalised and effective treatment strategies.

Learn more

MICROB-PREDICT Symposium connected to EASL School on Hepatology 2020 in Frankfurt

Management of acute-on-chronic liver failure
Location: Goethe University Frankfurt
Date: 02.07.2020
Course director: Prof. Jonel Trebicka
More information

More news

Successful 2nd General Assembly Meeting in Königstein, 22 January 2020

From 20 - 22 January 2020, 71 delegates of the MICROB-PREDICT consortium met in Königstein near Frankfurt a. M., Germany, to discuss the progress and results after the end of the first year of the project. We are happy to conclude that the project is in schedule and the first results come in nicely.

More events